We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood and Body Fluid Analyzer Developed for Medium-Sized Labs

By LabMedica International staff writers
Posted on 21 May 2009
Print article
A new, automatic analyzer has been developed for analysis of blood and body fluids in hospitals with medium-sized laboratories. The analyzer will play an important part in the diagnosis of a number of diseases, including different types of infection and leukemia.

Automated digital cell morphology is the process by which cells are automatically located on a stained peripheral blood or body fluid smear, preclassified, stored, and presented for confirmation by a technologist. The images then become available for access by physicians at any time for perusal.

Using the new analyzer laboratories can achieve time reductions (up to 50 %) and more standardized analyses. To count and classify white blood cells is a very common routine analysis in hematology laboratories. Trends indicate that medium-sized laboratories would like to automate the analytical process. Increased automation gives lab personnel more time and increases objectivity, safety, and standardization in the analytical work.

Called CellaVision DM1200, the instrument is CellaVision's (Lund, Sweden) next generation analyzer, and is the latest addition to the company's current range of products that include CellaVision DM96 and CellaVision DM8. The new instrument is based on a new cost-reduced hardware platform, is automated, and has a wider range of uses. Body fluid software can be added to the analyzer for analysis of fluids such as cerebrospinal fluid.

The official product launch will take place at the international Annual Meeting & Clinical Lab Expo AACC in Chicago, USA, on July 20-24, 2009. CellaVision DM1200 will be commercially available in Europe in around the same time.

CellaVision AB develops and markets systems for automatic differentials of white blood cells and erythrocyte morphology, and software for education and quality assurance of differentials.

Related Links:

CellaVision


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.